Clinical Features of Breast Cancer in South Korean Patients with Germline TP53 Gene Mutations

다국어 초록 (Multilingual Abstract)

Purpose: Li-Fraumeni syndrome (LFS) is a rare autosomal cancer syndrome caused by a germline mutation in the TP53 gene. Breast cancer in LFS patients is of various subtypes; however, limited data are available on the clinicopathological features of these subtypes and their appropriate treatments. This study aimed to review the clinical features and treatments for breast cancer in South Korean patients with germline TP53 mutations.
Methods: Data on the clinicopathological features and treatment of all breast cancer patients with LFS were collected retrospectively from the available database of 4 tertiary hospitals in the Republic of Korea.
Results: Twenty-one breast cancer cases in 12 unrelated women with confirmed germline TP53 mutations were included in the study. The median age at diagnosis was 33.5 years. The histopathological diagnosis included invasive ductal carcinoma (n = 16), ductal carcinoma in situ (n = 3), and malignant phyllodes tumor (n = 2). While 42% and 31% of the cases were positive for estrogen and progesterone receptors, respectively, 52.6% were human epidermal growth factor receptor 2 (HER2) positive, and 21% were triple-negative. The treatments included mastectomy (52%) and breast-conserving surgery (38%). Five patients underwent radiotherapy (RT). The median follow-up period was 87.5 (8–222) months. There were 3 ipsilateral and 4 contralateral breast recurrences during the follow-up, and 8 patients developed new primary cancers. In the post-RT subgroup, there were 2 ipsilateral and 2 contralateral breast recurrences in 1 patient, and 4 patients had a new primary cancer.
Conclusion: As reported in other countries, breast cancer in LFS patients in South Korea had an early onset and were predominantly but not exclusively positive for HER2.
A multidisciplinary approach with adherence to the treatment guidelines, considering mastectomy, and avoiding RT is encouraged to prevent RT-associated sequelae in LFS patients.

참고문헌 (Reference)

1 Mai PL, "Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort" 122 : 3673-3681, 2016

2 Bougeard G, "Revisiting LiFraumeni syndrome from TP53 mutation carriers" 33 : 2345-2352, 2015

3 Birch JM, "Relative frequency and morphology of cancers in carriers of germline TP53 mutations" 20 : 4621-4628, 2001

4 Goldgar DE, "Rare variants in the ATM gene and risk of breast cancer" 13 : R73-, 2011

5 Heymann S, "Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome" 5 : 104-, 2010

6 Hendrickson PG, "Radiation therapy and secondary malignancy in Li-Fraumeni syndrome : a hereditary cancer registry study" 9 : 7954-7963, 2020

7 Sjögren S, "Prognostic and predictive value of c-erbB-2overexpression in primary breast cancer, alone and in combination with other prognostic markers" 16 : 462-469, 1998

8 Tung NM, "Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology guideline" 38 : 2080-2106, 2020

9 Sidransky D, "Inherited p53 gene mutations in breast cancer" 52 : 2984-2986, 1992

10 Petitjean A, "Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype : lessons from recent developments in the IARC TP53 database" 28 : 622-629, 2007

11 Manié E, "High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors" 69 : 663-671, 2009

12 Hwang SJ, "Germline p53 mutations in a cohort with childhood sarcoma : sex differences in cancer risk" 72 : 975-983, 2003

13 Rosenberger LH, "Germline genetic mutations in a multi-center contemporary cohort of 550 phyllodes tumors : an opportunity for expanded multi-gene panel testing" 27 : 3633-3640, 2020

14 Le AN, "Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome" 181 : 181-188, 2020

15 Melhem-Bertrandt A, "Early onset HER2-positive breast cancer is associated with germline TP53 mutations" 118 : 908-913, 2012

16 Delia D, "Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations" 14 : 2137-2147, 1997

17 https, "Criteria for LFS | Li-Fraumeni Syndrome Association" Li-Fraumeni Syndrome Association

18 Cybulski C, "CHEK2 is a multiorgan cancer susceptibility gene" 75 : 1131-1135, 2004

19 Antoniou AC, "Breast-cancer risk in families with mutations in PALB2" 371 : 497-506, 2014

20 Masciari S, "Breast cancer phenotype in women with TP53 germline mutations : a Li-Fraumeni syndrome consortium effort" 133 : 1125-1130, 2012

21 강상율, "Breast Cancer Statistics in Korea in 2017: Data from a Breast Cancer Registry" 한국유방암학회 23 (23): 115-128, 2020

22 Narod SA, "BRCA mutations in the management of breast cancer : the state of the art" 7 : 702-707, 2010

23 de Bruin MA, "A young woman with bilateral breast cancer : identifying a genetic cause and implications for management" 11 : 512-517, 2013

24 Wilson JRF, "A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations" 47 : 771-774, 2010